Associations between adolescent cannabis use and brain structure in psychosis.

Szczegóły
Abstrakt

Tytuł:: Associations between adolescent cannabis use and brain structure in psychosis.
Autorzy:: Abush H; Department of Psychiatry, UT Southwestern Medical Center, Dallas TX, USA.
Ghose S; Department of Psychiatry, UT Southwestern Medical Center, Dallas TX, USA.
Van Enkevort EA; Department of Psychiatry, UT Southwestern Medical Center, Dallas TX, USA.
Clementz BA; Departments of Psychology and Neuroscience, BioImaging Research Center, University of Georgia, Athens GA, USA.
Pearlson GD; Department of Psychiatry, Yale University School of Medicine, New Haven CT, USA; Institute of Living, Hartford Hospital, Hartford CT, USA.
Sweeney JA; Department of Psychiatry, UT Southwestern Medical Center, Dallas TX, USA.
Keshavan MS; Department of Psychiatry, Harvard Medical School, Boston MA, USA.
Tamminga CA; Department of Psychiatry, UT Southwestern Medical Center, Dallas TX, USA.
Ivleva EI; Department of Psychiatry, UT Southwestern Medical Center, Dallas TX, USA. Electronic address: .
Źródło:: Psychiatry research. Neuroimaging [Psychiatry Res Neuroimaging] 2018 Jun 30; Vol. 276, pp. 53-64. Date of Electronic Publication: 2018 Mar 28.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Original Publication: Amsterdam : Elsevier
MeSH Terms:: Bipolar Disorder/*diagnostic imaging
Brain/*diagnostic imaging
Gray Matter/*diagnostic imaging
Marijuana Use/*epidemiology
Psychotic Disorders/*diagnostic imaging
Schizophrenia/*diagnostic imaging
Adolescent ; Adult ; Case-Control Studies ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Risk Factors ; Young Adult
References:: Chin Med J (Engl). 2002 Jun;115(6):819-23. (PMID: 12123544)
Am J Psychiatry. 2013 Nov;170(11):1263-74. (PMID: 23846857)
Biol Psychiatry. 2016 Apr 1;79(7):578-85. (PMID: 26344755)
Neurosci Biobehav Rev. 2014 Sep;45:85-99. (PMID: 24709070)
Biol Psychiatry. 2016 Apr 1;79(7):549-56. (PMID: 26386480)
Neurosci Biobehav Rev. 2013 Sep;37(8):1680-91. (PMID: 23769814)
Psychol Med. 2016 Mar;46(4):673-81. (PMID: 26568030)
Dev Cogn Neurosci. 2015 Dec;16:101-109. (PMID: 25953106)
JAMA Psychiatry. 2014 Dec 1;71(12):1323-31. (PMID: 25271938)
Schizophr Bull. 2014 Nov;40(6):1509-17. (PMID: 24345517)
Psychol Med. 2010 Aug;40(8):1337-47. (PMID: 19891810)
Arch Gen Psychiatry. 2011 Jun;68(6):555-61. (PMID: 21300939)
Neuropharmacology. 2011 Feb-Mar;60(2-3):235-43. (PMID: 20850463)
Arch Gen Psychiatry. 1989 Nov;46(11):1019-24. (PMID: 2818139)
J Psychiatr Res. 2013 Apr;47(4):438-44. (PMID: 23290558)
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64. (PMID: 22927402)
Schizophr Bull. 2015 Sep;41(5):1133-42. (PMID: 25548384)
Hum Brain Mapp. 2014 Jan;35(1):238-47. (PMID: 22996803)
Chem Phys Lipids. 2002 Dec 31;121(1-2):257-66. (PMID: 12505705)
Am J Psychiatry. 2005 Dec;162(12):2233-45. (PMID: 16330585)
J Psychopharmacol. 2004 Dec;18(4):502-8. (PMID: 15582916)
Drug Alcohol Depend. 2005 Jan 7;77(1):23-30. (PMID: 15607838)
Psychopharmacology (Berl). 2009 Jul;205(1):45-52. (PMID: 19326102)
Schizophr Res. 2004 Jun 1;68(2-3):283-97. (PMID: 15099610)
Physiol Genomics. 2000 Sep 08;3(3):175-85. (PMID: 11015613)
Neuropsychopharmacology. 2008 Oct;33(11):2760-71. (PMID: 18172430)
Schizophr Res. 2001 Mar 1;48(1):109-23. (PMID: 11278158)
Neuroimage. 2001 Jul;14(1 Pt 1):21-36. (PMID: 11525331)
Schizophr Bull. 2010 Nov;36(6):1115-30. (PMID: 19386576)
Synapse. 2006 Nov;60(6):429-36. (PMID: 16881072)
Schizophr Bull. 2016 Nov;42(6):1496-1503. (PMID: 27033329)
J Cereb Blood Flow Metab. 1992 Nov;12 (6):900-18. (PMID: 1400644)
Brain Struct Funct. 2016 Jan;221(1):407-19. (PMID: 25348266)
Hippocampus. 2009 Aug;19(8):763-72. (PMID: 19156848)
Schizophr Res. 2012 Jul;138(2-3):183-7. (PMID: 22475382)
Br J Pharmacol. 2005 Dec;146(7):913-5. (PMID: 16205721)
Psychiatry Res. 2012 Oct 30;204(1):13-24. (PMID: 23177922)
Arch Gen Psychiatry. 2004 Jul;61(7):649-57. (PMID: 15237077)
Neuroimage. 2007 Oct 15;38(1):95-113. (PMID: 17761438)
J Psychopharmacol. 2006 Sep;20(5):611-21. (PMID: 16714325)
Psychol Med. 2012 Apr;42(4):705-16. (PMID: 21899795)
Am J Psychiatry. 2017 Jun 1;174(6):586-594. (PMID: 28359200)
Twin Res Hum Genet. 2012 Jun;15(3):401-13. (PMID: 22856374)
BMC Psychiatry. 2009 Nov 16;9:71. (PMID: 19917116)
Eur Neuropsychopharmacol. 2007 Mar;17(4):289-97. (PMID: 17137758)
Psychopharmacology (Berl). 2016 Mar;233(5):809-21. (PMID: 26621349)
Schizophr Res. 2010 Jul;120(1-3):95-100. (PMID: 20483565)
Biol Psychiatry. 2017 Jul 1;82(1):26-39. (PMID: 27817844)
Neuropsychopharmacology. 2008 Apr;33(5):1113-26. (PMID: 17581536)
Biol Psychiatry. 2015 Sep 15;78(6):403-12. (PMID: 25802081)
Am J Psychiatry. 2013 Nov;170(11):1285-96. (PMID: 24185241)
Curr Mol Med. 2003 Aug;3(5):427-36. (PMID: 12942996)
Schizophr Bull. 2012 Mar;38(2):316-30. (PMID: 20660494)
J Child Psychol Psychiatry. 2007 Jun;48(6):592-600. (PMID: 17537075)
Psychiatry Res. 2007 May 30;151(1-2):151-4. (PMID: 17383738)
Schizophr Bull. 1991;17(4):597-608. (PMID: 1805353)
J Neurosci. 2014 Apr 16;34(16):5529-38. (PMID: 24741043)
Schizophr Res. 2005 Mar 1;73(2-3):369-71. (PMID: 15653284)
Neuropsychopharmacology. 2003 Oct;28(10 ):1760-9. (PMID: 12888772)
Acta Psychiatr Scand. 2008 Sep;118(3):209-13. (PMID: 18452569)
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1054-63. (PMID: 17482741)
Arch Gen Psychiatry. 2011 Feb;68(2):128-37. (PMID: 21300943)
Nat Neurosci. 2015 May;18(5):773-8. (PMID: 25821911)
Biol Psychiatry. 2013 Sep 15;74(6):427-35. (PMID: 23790226)
J Psychopharmacol. 2005 Mar;19(2):187-94. (PMID: 15871146)
Schizophr Res. 2005 Jun 1;75(1):135-7. (PMID: 15820332)
Schizophr Res. 2015 Sep;167(1-3):18-27. (PMID: 25601362)
Neurosci Lett. 2012 Mar 9;511(2):89-94. (PMID: 22306089)
Schizophr Bull. 2012 Jun;38(4):873-80. (PMID: 21389110)
Curr Pharm Des. 2012;18(32):5070-80. (PMID: 22716152)
Schizophr Res. 2011 May;128(1-3):111-6. (PMID: 21420282)
Schizophr Res. 2015 Oct;168(1-2):245-51. (PMID: 26235754)
Dev Cogn Neurosci. 2015 Dec;16:16-22. (PMID: 26507433)
Psychol Med. 2008 Sep;38(9):1257-66. (PMID: 18005495)
Biol Psychiatry. 2005 May 15;57(10):1117-27. (PMID: 15866551)
Curr Pharm Des. 2012;18(32):5131-40. (PMID: 22716160)
Neuroimage. 2000 Jun;11(6 Pt 1):805-21. (PMID: 10860804)
Biol Psychiatry. 1999 Jan 1;45(1):17-25. (PMID: 9894571)
Schizophr Res. 2008 Feb;99(1-3):1-6. (PMID: 18248793)
Biol Psychiatry. 1998 Jul 15;44(2):88-97. (PMID: 9646890)
Arch Gen Psychiatry. 2008 Jun;65(6):694-701. (PMID: 18519827)
Grant Information:: R01 MH078113 United States MH NIMH NIH HHS; R01 MH077945 United States MH NIMH NIH HHS; R01 MH077852 United States MH NIMH NIH HHS; R01 MH077851 United States MH NIMH NIH HHS; R01 MH077862 United States MH NIMH NIH HHS; K23 MH102656 United States MH NIMH NIH HHS
Contributed Indexing:: Keywords: Cannabis; Gray matter density; Psychotic bipolar disorder; Schizophrenia; Voxel Based Morphometry
Entry Date(s):: Date Created: 20180410 Date Completed: 20190422 Latest Revision: 20190816
Update Code:: 20240104
PubMed Central ID:: PMC5959798
DOI:: 10.1016/j.pscychresns.2018.03.008
PMID:: 29628270
: Czasopismo naukowe

Full Text Finder

Associations between cannabis use and psychotic disorders suggest that cannabis may be a contributory risk factor in the neurobiology of psychosis. In this study, we examined brain structure characteristics, total and regional gray matter density (GMD), using Voxel Based Morphometry, in psychotic individuals, stratified by history of cannabis use (total n = 109). We also contrasted GMD estimates in individual diagnostic groups (schizophrenia/bipolar I disorder) with and without history of adolescent cannabis use (ACU). Individuals with psychosis as a whole, both with and without history of ACU, had lower total and regional GMD, compared to healthy controls. ACU was associated with attenuated GMD reductions, compared to non-users, especially in the schizophrenia cases, who showed robust GMD reductions in fronto-temporal and parietal cortex, as well as subcortical regions. Notably, total and regional GMD estimates in individuals with psychosis and ACU were not different from controls with no ACU. These data indicate that the history of ACU in psychotic individuals is associated with attenuated GMD abnormalities. Future investigations targeting potential unique etiological and risk factors associated with psychosis in individuals with ACU may help in understanding of the neurobiology of psychotic disorders and novel treatment options for these individuals.
(Copyright © 2018 Elsevier B.V. All rights reserved.)

Informacja